1. Introduction {#sec1-cancers-11-00132}
===============

Female carriers of pathogenic variants of the *BRCA1 (path_BRCA1*) gene have risks for breast and ovarian cancer. Early diagnosis and treatment have not been demonstrated to cure all those having breast cancer \[[@B1-cancers-11-00132]\] nor those with ovarian cancer \[[@B2-cancers-11-00132]\], for which reasons prophylactic bilateral mastectomy (PBM) and prophylactic salpingo-oophorectomy (PBSO) are accepted options. Precise estimates of risk by age for breast or ovarian cancer in the carriers of *path_BRCA1* variants are important when selecting if and when to undertake PBSO or PBM.

In a series of reports, we have previously described the Norwegian frequent *path_BRCA1* variants \[[@B3-cancers-11-00132],[@B4-cancers-11-00132],[@B5-cancers-11-00132],[@B6-cancers-11-00132],[@B7-cancers-11-00132],[@B8-cancers-11-00132]\]. Some details relevant to the present report are mentioned below. Included in these previous reports is a description of the underlying genetic paradigms with references. This may be summarized as follows: 25--30 generations ago, the Bubonic plagues killed most of the Norwegian population, leaving about 200,000 survivors. They grouped in small geographical isolates, followed by a rapid population expansion by in-mating inside these isolates until three generations ago, when modern communications allowed contact between the separated populations. Because of the population collapse, Norway as an independent state no longer existed, and the sailing traditions from the Viking ages could not be continued. When warships equipped with cannons later were invented, the traditional Norwegian ships could not accommodate the cannons. Thus, the Norwegian population was for practical reason isolated from the rest of the world until the end of the Napoleon wars in 1815. At this time, the population had expanded and was starving, and about half of the population emigrated to USA/Canada to survive. In sum, 200,000 survivors of the Bubonic plagues by in-mating in small geographical isolates expanded to about 10 million today, when counting the emigrants to USA/Canada. Assuming a 0.3% prevalence of *path_BRCA1* variants, the 200,000 survivors of the Bubonic plagues should have 600 *path_BRCA1* alleles. The probability for each one of these to survive in a stable population until today should be about 5%, which should in this case amount to 30 different *path_BRCA1* alleles. Genetic drift due to population bottlenecks and expansion, combined with in-mating in isolated populations may substantially change the expectations described above, and also the relative prevalence of each of the surviving *path_BRCA1* alleles. When describing the epidemiology of the *path_BRCA1* variants in Norway, we attributed the variations to genetic drift and one or a few hotspots for de novo germline mutations.

In 1999, we initially reported that our prospective findings indicated that carriers of the most frequent *path_BRCA1* variants had lower incidence for infiltrating breast cancer than other *path_BRCA1* carriers \[[@B3-cancers-11-00132]\]. We confirmed this ten years later with our updated series \[[@B4-cancers-11-00132]\]. In 2013, we reported that the most frequent Polish *path_BRCA1* variant had the same lower incidence for breast cancer as the Norwegian frequent *path_BRCA1* variants, while the North-American less frequent *path_BRCA1* variants implied higher risk for infiltrating breast cancer, similar to the less frequent Norwegian *path_BRCA1* variants \[[@B5-cancers-11-00132]\].

In 2007, we reported that 2.5% of our incident breast cancer cases had one of the frequent Norwegian *path_BRCA1* variants, while 23% of the incident ovarian cancers had one of these variants \[[@B6-cancers-11-00132]\]. Bearing in mind that the population incidence of breast cancer is about 10 times the incidence of ovarian cancer, these findings indicated that the risks for breast and ovarian cancers were similar in carriers of the Norwegian founder *path_BRCA1* variants, but with later onset of ovarian cancer. This confirmed our results from segregation analyses in these families, in that lifetime risks for breast and ovarian cancer in the former generation were similar \[[@B7-cancers-11-00132]\]. Before a significant number of breast cancer cases were cured through modern health care, young onset breast cancer was a common cause of death in the *path_BRCA1* carriers. This is probably related to why the gene was named a BReast CAncer gene and an early perception was that *path_BRCA1* was predominantly causing disease in young adult women. The high lifetime incidence for ovarian cancer has in recent years been illustrated through some early-onset breast cancers being cured, and in carriers having undertaken PBM.

We have previously demonstrated that the most frequent *path_BRCA1* variant in Norway are located in poly-A tract of the gene (chr17:41246515-41246559 ATAGGCGGACTCCCAGCACAG[AAAAAAA]{.ul}GGTAGATCTGAATGCTG (normal reverse complement, poly-A sequence into which an extra A is inserted the into the poly-A part in the pathogenic allele)). This may theoretically indicate hot-spots for recurrent de novo mutations, and we have demonstrated that the most frequent *path_BRCA1* variant in our series occurs in different haplotypes world-wide. We interpret this to reflect that this part of the gene is a hot-spot for de novo mutations. We also find that all examined Norwegian carriers have the same haplotype, as would be expected as a result of local genetic drift \[[@B8-cancers-11-00132]\].

We decided to examine cancer incidence in fertile ages for the frequent *path_BRCA1* variants in Norway based on the methods developed for estimating cancer incidences in the Prospective Lynch Syndrome Database (PLSD) \[[@B9-cancers-11-00132]\]. We hypothesized that the frequent *path_BRCA1* variants should not have reduced fitness, and we in this study used penetrance in fertile ages as a surrogate marker for fitness. Until recent generations, most children were born by mothers aged less than 35 years, and it is well recognized that dominantly inherited disorders implying reduced fitness below this age are rare, and that the prevalence is maintained by de novo mutations. In addition, a recent report by \[[@B10-cancers-11-00132]\] describing the average incidence of breast cancer in *path_BRCA1* carriers provided the opportunity to compare the incidence of breast cancer in carriers of our frequent *path_BRCA1* carriers with the average incidence from other countries.

2. Material and Methods {#sec2-cancers-11-00132}
=======================

2.1. Patients and ethics {#sec2dot1-cancers-11-00132}
------------------------

We have previously described in detail how we from 1988 onwards established an out-patient inherited cancer clinic, a combined electronical medical file and a research registry holding all information received from all patients. Likewise, we established a biobank with blood sample from the genetically tested patients including informed consent for research studies \[[@B6-cancers-11-00132]\]. All genetic testing was performed according to national legislation for clinical use. All patients filed had either referred themselves or had been referred by other hospitals/physicians. All patients were followed with annual mammography and annual breast MRI for breast cancer, and with transvaginal ultrasound and blood CA 125 for ovarian cancer. The study was approved by the Ethical review board (No. S02030) and by The Norwegian Data Inspectorate (No. 2001/2988--2).

2.2. Material and Methods {#sec2dot2-cancers-11-00132}
-------------------------

For the present study, we updated our series and calculated cumulative incidence by age with a more precise method than that used in our previous reports as referenced above. These methods have been described in detail elsewhere \[[@B9-cancers-11-00132]\]. In brief, the methods calculate annual incidence rate in five-year cohorts and then calculate cumulative risk by age based on these. Doing so, differences of cancer incidences by age, different numbers of patients in the different age groups, and inclusion of patients at different ages are adjusted, corresponding to how cancer registries calculate cumulative incidences. Age at first prospectively planned and executed examination was used as inclusion point for follow-up.

When considering ovarian cancer incidence, all cases with oophorectomy for any reason before or at inclusion were excluded. The first ovarian cancer diagnosed after inclusion was scored as event, and any other cancer---including breast cancer---was ignored. Series were right-censored at oophorectomy for any reason or last examination, whichever came first.

When considering breast cancer incidence, all cases with breast cancer before or at inclusion were excluded, as were all cases with oophorectomy for any reason before or at inclusion. First breast cancer diagnosed after inclusion was scored as event. Besides ovarian cancer implying oophorectomy, any other cancer was ignored. Cases with mastectomy for any reason prior to or at the same age as inclusion were excluded, and series were right-censored if oophorectomy for any reason, mastectomy, breast cancer or last examination, whichever came first. Because of right-censoring at first breast cancer, this report contains no information on synchronous or meta-synchronous breast cancers.

According to national guidelines, follow-up was initiated from 25 years of age onwards, to the end that we have no information on annual incidence of cancer before that age, while we do have complete records of cancer before 25 years of ages used for the selection of patients to be studied as mentioned above. Annual incidence rates (AIR) in 5-year cohorts were calculated. Risk for cancer at age 25 years was set to zero as starting point for calculating cumulative incidences. Incidence rates of cancer past childbearing ages were not the foci for the present study, and because of high uptake of PBSO, the number of follow-up years was insufficient to calculate incidence rates in 5-year age cohorts after 50 years of age with the methods employed. Similarly, we did not have enough observation years to calculate annual incidence of breast cancer in fertile ages after oophorectomy, because survival after ovarian cancer has been very poor, and because PBSO before the end of childbearing ages has not been implemented. Previously, we have scored infiltrating cancer only as event, while we for this report decided to use the recent report by \[[@B10-cancers-11-00132]\] as contrast group, and thus included carcinoma in situ as event, as they did. As a methodological control, we applied our algorithms as previously described \[[@B9-cancers-11-00132]\], using the follow-up years and events given by \[[@B10-cancers-11-00132]\], and came to similar cumulative risks in their series as they did with their methods.

Fishers' exact test was used for comparisons of breast cancer incidence in the specified age cohorts. A detailed description of the methods used to consider the differences between distributions is included as on-line [supplementary material S1](#app1-cancers-11-00132){ref-type="app"}.

3. Results {#sec3-cancers-11-00132}
==========

When the series were censored for the current study, all families meeting our criteria for being genetically tested had been examined for the 8 most frequent *path_BRCA1* variants \[[@B6-cancers-11-00132]\]. Also, a large number of them had been examined for other Norwegian *path_BRCA1* variants or were fully *BRCA1* sequenced. In line with our previous reports, *BRCA1* c.1016insA, c.1556delA, c.3228delAG and c.697delGT were grouped as frequent, and the others as infrequent. Among 1918 demonstrated carriers of *path_BRCA1* variants, 1055 (55%) had one out of the four most frequent variants.

Distribution of observation years, cancer cases and annual incidence rates (AIR) as events/observation years, starting at 25 years of age, is given in [Table 1](#cancers-11-00132-t001){ref-type="table"}. No ovarian cancer was observed before 35 years of age. Cumulative risks for breast cancer as calculated from the annual incidence rates in the 5-year cohorts are given in [Table 2](#cancers-11-00132-t002){ref-type="table"}, and are illustrated in [Figure 1](#cancers-11-00132-f001){ref-type="fig"}. The distribution of numbers with each single separate variant is illustrated in [Figure 2](#cancers-11-00132-f002){ref-type="fig"} and where the four frequent variants are identified. [Table 3](#cancers-11-00132-t003){ref-type="table"} describes all *path_BRCA1* variants and their prevalence. As seen, the carriers of frequent *path_BRCA1* variants had lower cumulative incidence of breast cancer than carriers of infrequent *path_BRCA1* variants (*p* = 0.05 at age 40, *p* = 0.02 at age 45 years). The cumulative incidences for breast cancer for carriers of each of the four frequent *path_BRCA1* variants are illustrated in [Figure 3](#cancers-11-00132-f003){ref-type="fig"}: one carrier of *BRCA1c.3822delAG* developed breast cancer before 35 years of age, and none in the others. This was the only breast cancer detected before 35 years of age in carriers of any of the eight most frequent *path_BRCA1* variants.

Compared to the average cumulative risk for *path_BRCA1* carriers elsewhere reported by \[[@B10-cancers-11-00132]\], the carriers of Norwegian frequent *path_BRCA1* variant had significantly lower cumulative incidences (*p* = 0.0001 at ages 40 and 45 years).

As seen in supplementary eFigure1a in the report by \[[@B10-cancers-11-00132]\]., they observed no breast cancer before 25 years of age, to the end that when we set the cumulative incidence in their series to zero for the comparisons applying our methods presented here, this implies no error. On the other hand, not having access to the exact number of observation years from 25--30 years in their series, we used their average annual incidence rate from 20--30 years indicated in their [Table 3](#cancers-11-00132-t003){ref-type="table"} when calculating cumulative incidence from 25--30, which resulted in a slight underestimation of the cumulative risk in their series (24% at age 40 calculated by us as seen in [Table 2](#cancers-11-00132-t002){ref-type="table"}, compared to their reported 26% at age 40). This difference had no impact on the conclusions in this report: if we had calculated the significance for difference between their series using their point estimates and confidence intervals and our frequent *path_BRCA1* variants, the p-values given in [Table 2](#cancers-11-00132-t002){ref-type="table"} would have been lower.

Comparing the annual incidence rates for breast cancer in the age group 21 to 29 years, the point estimate for observed incidence rate in carriers of infrequent *path_BRCA1* variants was higher (13 events in 596 observation years; AIR 2.2% (95%CI 1.7--3.7%)) than in carriers of frequent *path_BRCA1* variants (8 events in 887 observation years; AIR 0.9% (95%CI 0.4--1.8%)) but insignificantly so (*p* \> 0.05). Comparing the incidence in carriers of our frequent *path_BRCA1* variants with the corresponding annual incidence rate reported as average for *path_BRCA1* carriers by \[[@B10-cancers-11-00132]\], the average cumulative incidence reported by Kuchenbaecker et al. was significantly higher (83 events in 3,348 observation years; AIR 2.5% (95% CI 2.0--3.1%)), than in our carriers of frequent *path_BRCA1* carriers (Fisher exact *p* = 0.03).

No carrier of frequent *path_BRCA1* variants in our series had any cancer before or at inclusion, corresponding with the inclusion criteria used by \[[@B10-cancers-11-00132]\].

4. Discussion {#sec4-cancers-11-00132}
=============

The most frequent *path_BRCA1* variants in our series had low penetrance in fertile ages, and the penetrance was lower in carriers of infrequent *path_BRCA1* variants in our series, and lower than the population average for *path_BRCA1* carriers reported by others. Infrequent *path_BRCA1* variants had penetrance in fertile ages similar to the population average for the *path_BRCA1* variants elsewhere reported. Our report is to our knowledge the first report focusing cancer incidence in fertile ages in prospectively detected carriers of *path_BRCA1* variants in order to consider why some *path_BRCA1* variants become more frequent than others.

For a de novo mutation to survive, the carrier has to produce children: to escape Darwinian de-selection, the carriers have to be healthy during fertile ages. This is why, in general, all dominantly inherited disorders with serious prognosis manifesting themselves in young adult ages are de-selected. Their prevalence in the population is a balance between de novo mutations and Darwinian de-selection.

The most frequent *path_BRCA1* variants in our series is one additional A in a poly-A part of the *BRCA1* gene, theoretically indicating increased probability for this pathogenic variant to be inserted into the population more than once. This variant is indeed reported from other countries to have occurred more than once, as indicated by the occurrence on multiple different *BRCA1* haplotypes, one of these being prevalent in the Norwegian population \[[@B8-cancers-11-00132]\].

Previously, we have discussed that the probability for a random pathogenic variant to become frequent increases with inbreeding in expanding populations \[[@B11-cancers-11-00132]\], which indeed is the history for the Norwegian population through the last 600 years.

In summary, we now have described three independent factors which may all have contributed to make the most frequent Norwegian *path_BRCA1* variants frequent: Less de-selection because of lower risk for cancer in fertile ages, hot-spot for de novo mutations, and a high probability for genetic drift in areas of inbreeding in an expanding population.

Our results are derived from intense screening of *path_BRCA1* carriers aiming at early detection and cure to improve prognosis \[[@B1-cancers-11-00132]\]. Breast cancer screening implies over-diagnosing \[[@B12-cancers-11-00132]\]. If the series reported by \[[@B10-cancers-11-00132]\]. had been subjected to less intense screening, the differences between their average results for *path_BRCA1* carriers and our series of frequent *path_BRCA1* carriers may be artificially low, which would strengthen the conclusions in this report. Reference \[[@B10-cancers-11-00132]\] did not mention whether or not the first (prevalent) round cancers were included when calculating annual incidence rates. If the prevalent round findings were included in their series, their reported annual incidence rates would be artificially too high. This would be a confounder to the conclusions in this report, but this would have no impact for the internal comparison of frequent versus infrequent *path_BRCA1* variants in our series which was the original only focus for this report. We have performed one predetermined test with the same categorization of our series comparing the four most frequent variants versus infrequent variants keeping the same categorizations as in our previous reports: we have not done multiple testing in our material, which in case should have been corrected for when calculating the *p*-values.

In addition to inform on the mechanisms making some *path_BRCA1* variants frequent, our findings may be of interest for Norwegian carriers of *path_BRCA1* variants when considering if, and if so at which age, to undertake PBM.

5. Conclusions {#sec5-cancers-11-00132}
==============

Considering the incidence of cancer in fertile ages as a surrogate marker of fertility/fitness, and based on the theory of Mendelian deselection when reduced fitness, we expected and confirmed that carriers of the most frequent Norwegian *path_BRCA1* variants had lower incidence of cancer in fertile ages than carriers of less frequent *path_BRCA1* variants. This adds to our previous reports demonstrating that the distribution of *path_BRCA1* variants are influenced by genetic drift and hot-spot for de novo mutations. Besides being of theoretical interest to explain why some *path_BRCA1* variants are more frequent than others, this is of interest to female variant carriers who are to decide if, and if so at which age, to undertake prophylactic mastectomy.

Sigve Nakken calculated the confidence intervals to and *p*-values for differences between the cumulative incidences.

The following are available online at <http://www.mdpi.com/2072-6694/11/2/132/s1>, Methods for estimating and comparing incidence rates that vary with subjects' age.

###### 

Click here for additional data file.
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![Breast cancer cumulative incidences in female carriers of frequent Norwegian *path\_ BRCA1* variants (blue line), infrequent (red line) and contrast group (black line) starting from 25 years of age.](cancers-11-00132-g001){#cancers-11-00132-f001}

![Number of carriers with each separate *path_BRCA1* variant demonstrated. The four variants in this and previous reports grouped as frequent are indicated.](cancers-11-00132-g002){#cancers-11-00132-f002}

![Separate cumulative incidences of breast cancer in carriers of the four most frequent *path_BRCA1* variants.](cancers-11-00132-g003){#cancers-11-00132-f003}

cancers-11-00132-t001_Table 1

###### 

Number observation years, number of events and annual incidence rates (events/observation years, AIR) in 25-year cohorts from 25 years of age onwards. 25yrs: observation years 25--29 years; 25ca: cancers observed 25--29 years; AIR25: annual incidence rate from 25 years of age included to 29 years included with 95% confidence intervals for breast cancer incidences; AIR30, AIR40 and AIR45 likewise.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer Type      *Path_BRCA1* Variant   25yrs   25ca               AIR25\             30yrs   30ca                   AIR30\         35yrs   35ca                   AIR35 (95%CI)          40yrs   40ca                   AIR40 (95%CI)          45yrs   45ca                   AIR45\
                                                                     (95%CI)                                           (95%CI)                                                                                                                                                   (95%CI)
  ---------------- ---------------------- ------- ------------------ ------------------ ------- ---------------------- -------------- ------- ---------------------- ---------------------- ------- ---------------------- ---------------------- ------- ---------------------- ----------------------
  Ovarian cancer   Frequent               48      0                  0                  161     0                      0              173     1                      0.0058                 115     5                      0.0435                 33      1                      0.0303

  Infrequent       36                     0       0                  100                0       0                      107            0       0                      80                     1       0.0125                 28                     2       0.0714                 

  Breast cancer    Frequent               165     1                  0.006 (0--0.034)   463     0                      0 (0--0.008)   414     8                      0.019 (0.008--0.038)   219     4                      0.018 (0.005--0.047)   80      2                      0.025 (0.003--0.090)

  Infrequent       134                    1       0.008 (0--0.041)   299                3       0.010 (0.002--0.029)   297            10      0.034 (0.016--0.062)   173                    6       0.034 (0.013--0.076)   95                     3       0.032 (0.006--0.093)   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cancers-11-00132-t002_Table 2

###### 

Cumulative incidence from age 25 years set to zero up to given age, 95% confidence intervals and p-values for differences between cumulative incidence in carriers of frequent *path_BRCA1* variants in Norway compared to carriers of infrequent variants in Norway and compared to average reported by \[[@B10-cancers-11-00132]\].

  *Path_BRCA1* Variant   From 25 Years of Age to   Cumulative Incidence   95% Confidence Interval   *p*-Value Versus Infrequent   *p*-Value Versus Kuchenbaeker et al.
  ---------------------- ------------------------- ---------------------- ------------------------- ----------------------------- --------------------------------------
  Frequent               40 years                  12%                    4--20%                    0.05                          0.0001
  45 years               20%                       10--30%                0.02                      0.0001                        
  50 years               29%                       14--45% \*             0.09 \*                   0.01 \*                       
  Infrequent             40 years                  23%                    12--34%                                                 
  45 years               35%                       22--48%                                                                        
  50 years               45%                       30--60% \*                                                                     
  Kuchenbaeker et al.    40 years                  24%                    21--28%                                                 
  45 years               35%                       32--39%                                                                        
  50 years               45%                       41--49%                                                                        

**\*** Wider confidence intervals and corresponding higher *p*-values in old ages in our series due to low numbers, because of high uptake prophylactic salpingo-oophorectomy (PBSO) past childbearing ages.

cancers-11-00132-t003_Table 3

###### 

*Path_BRCA1* variants detected.

  *BRCA1* Variant                               Number of Carriers
  --------------------------------------------- --------------------
  c.1016dupA                                    366
  c.1556delA                                    337
  c.3228_3229delAG                              193
  c.697_698delGT                                159
  c.3178G\>T                                    119
  c.4745delA                                    63
  c.1A\>C                                       49
  c.2351_2357delCGTTACT                         47
  c.5075-2A\>C                                  37
  c.3084_3094delTAATAACATTA                     36
  c.5047G\>T                                    35
  c.(441 + 1_442--1)\_(4357 + 1_4358--1)del     24
  c.(4185 + 1_41861)\_(4357 + 1_4358--1)dup     22
  c.3607C\>T                                    22
  c.3048_3052dupTGAGA                           21
  c.5266dupC                                    20
  c.3331_3334delCAAG                            20
  c.(5332 + 1_5333--1)\_(5406 + 1_5407--1)del   19
  c.1072delC                                    18
  c.5511G\>A                                    15
  c.1450G\>T                                    14
  c.(80 + 1_81--1)\_(4986 + 1_4987--1)del       12
  c.5513T\>G                                    12
  c.66dupA                                      12
  c.2475delC                                    11
  c.3966delA                                    11
  c.2869C\>T                                    10
  c.2591C\>G                                    10
  c.1058G\>A                                    10
  c.3319G\>T                                    10
  c.4065_4068delTCAA                            9
  c.5407-25T\>A                                 8
  c.1292dupT                                    7
  c.2558ins356                                  7
  c.3874delT                                    6
  c.68_69delAG                                  6
  c.5251C\>T                                    6
  c.5534C\>A                                    5
  c.1687C\>T                                    5
  c.(?\_1--1)\_(4357 + 1_4358--1)del            5
  c.794_795delCT                                5
  c.5503C\>T                                    5
  c.3710delT                                    5
  c.4035delA                                    4
  c.2989_2990dupAA                              4
  c.4689C\>G                                    4
  c.3319G\>T                                    4
  c.5213G\>A                                    4
  c.4300_4301delA                               4
  c.115T\>G                                     4
  c.5153G\>C                                    3
  c.848T\>A                                     3
  c.339_361dup                                  3
  c.4612C\>T                                    3
  c.(?\_1--1)\_(134 + 1_135--1)del              3
  c.457_458ins21                                3
  c.3770_3771delAG                              3
  c.2869C\>T                                    3
  c.3700_3704delGTAAA                           2
  c.3477_3479delAAAinsC                         2
  c.3835_3835delG                               2
  c.2438dupG                                    2
  c.2389G\>T                                    2
  c.1695dupG                                    2
  c.65T\>C                                      2
  c.1287_1287delA                               2
  c.385_385delG                                 2
  c.2681_2682delAA                              2
  c.4932_4933dupAA                              2
  c.4972_4972delA                               2
  c.(5074 + 1_5075--1)\_(5592 + 1\_?-1)del      2
  c.(134 + 1_135--1)\_(441 + 1_442--1)del       2
  c.241C\>T                                     1
  c.5434C\>G                                    1
  c.3817C\>T                                    1
  c.2722G\>T                                    1
  (4185 + 1_41861)\_(4357 + 1_4358--1)del       1
  c.4883T\>C                                    1
  c.1059G\>A                                    1
  c.5123C\>T                                    1
  c.3937C\>T                                    1
  c.140G\>T                                     1
  c.1961dupA                                    1
  c.3808T\>G                                    1
  c.(5193 + 1_5194--1)\_(5592 + 1\_?-1)del      1
  c.514C\>T                                     1
  c.2185G\>T                                    1
  c.4689C\>G                                    1
  c.130T\>A                                     1
  c.4987-16T\>G                                 1
  c.1674_1674dupA                               1
  c.2745_2748delTCAA                            1
  c.5075A\>C                                    1
  c.(4675 + 1_4676--1)\_(4986 + 1_4987--1)del   1
  c.929delA                                     1
  c.3005delA                                    1
  c.5212G\>A                                    1
  Sum                                           1918
